Currently, there are 333.93M common shares owned by the public and among those 270.44M shares have been available to trade.
The company’s stock has a 5-day price change of -50.00% and -69.24% over the past three months. IOVA shares are trading -76.35% year to date (YTD), with the 12-month market performance down to -87.48% lower. It has a 12-month low price of $2.70 and touched a high of $13.60 over the same period. IOVA has an average intraday trading volume of 10.34 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -45.87%, -48.90%, and -76.16% respectively.
Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 64.51% of the company’s 333.93M shares outstanding.
It has a market capitalization of $584.38M and a beta (3y monthly) value of 1.07. The earnings-per-share (ttm) stands at -$1.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.63% over the week and 8.54% over the month.
Earnings per share for the fiscal year are expected to increase by 11.71%, and 39.94% over the next financial year. EPS should grow at an annualized rate of 80.92% over the next five years, compared to 4.17% over the past 5-year period.
UBS coverage for the Iovance Biotherapeutics Inc (IOVA) stock in a research note released on October 24, 2024 offered a Buy rating with a price target of $17. Piper Sandler was of a view on July 29, 2024 that the stock is Neutral, while Goldman gave the stock Buy rating on November 20, 2023, issuing a price target of $12. Barclays on their part issued Overweight rating on September 18, 2023.
